Compare ICU & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICU | NXL |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 10.2M |
| IPO Year | N/A | N/A |
| Metric | ICU | NXL |
|---|---|---|
| Price | $3.06 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 82.2K | ★ 810.7K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.00 | $15.52 |
| Revenue Next Year | $50.00 | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.31 |
| 52 Week High | $5.10 | $2.00 |
| Indicator | ICU | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 40.14 |
| Support Level | $2.26 | $0.35 |
| Resistance Level | $4.96 | $0.48 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 41.46 | 6.78 |
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.